日韩成人在线网站_国产精品观看_丝袜美腿中文字幕_涩涩app_欧美猛男大巨大1069_777在线视频_西西人体大胆4444www_九月色婷婷_天堂中文在线看_日本精品一级_午夜影院久久_男生操女生的_日本 奴役 捆绑 受虐狂_91免费在线播放_成人黄色免费观看

Founded in 2015, Beike Nanotechnology Co., Ltd. is a professional Nanomedicine Contract Research Organization (CRO) in China. The company has R&D centers or production bases in Beijing, Suzhou and Wuxi. The company mainly provides nanochemical drugs (including starting materials, intermediates, APIs, preparations) and nanobiological drugs (including plasmids) required for the whole life cycle from early clinical research to drug launch for hospitals, pharmaceutical companies, and new drug R&D institutions. , viral vectors, cell therapy, gene therapy) custom R&D and production services. As a high-tech enterprise, we provide customers with excellent end-to-end scientific research CRO services, aiming to develop new nanomaterials and their application technologies and products in the fields of life science, biomedicine, and biodetection, and provide relevant scientific research institutions and drug research and development. The unit provides technical support and cooperative research services for nanomedicine.
We are committed to becoming an open, innovative and reliable nanomedicine service platform, so that nanotechnology can benefit the field of life sciences earlier. After ten years of precipitation, the company has a leading R&D nanotechnology platform capability, perfect quality management, and provides customers with core services and various scientific research service support from small test, pilot test, scale-up to commercial production. Provide long-term services for well-known hospitals, pharmaceutical companies and drug research and development institutions in the country. The service content involves the treatment of major diseases such as anti-AIDS, hepatitis, diabetes, tumor, analgesia, anti-heart failure, hypolipidemic, insomnia, epilepsy, anti-influenza, anti-allergy and so on.
We insist on driving the high-quality development of enterprises with technological innovation, continuously strengthen innovation investment, and actively promote the R&D of key core technologies and the construction of innovative talent teams, with a R&D technical team of more than 20 people. By the end of 2021, the company has authorized 8 invention patents, has applied for more than 100 patents in total, and published more than 20 SCI papers annually.